Hepatic cysteamine and non-protein sulfhydryl levels following cystamine or cysteamine treatment of galactosamine-poisoned rats.
Hepatic cysteamine and non-protein sulfhydryl (NPSH) levels were determined in galactosamine (GAL)-poisoned rats following hepatoprotective cystamine or cysteamine treatments to determine whether alterations of hepatic NPSH status could contribute to their observed protective actions. D(+)-Galactosamine HC1 (400 mg/kg, ip) was administered to male Sprague-Dawley rats at 8 pm. Cystamine diHC1 (300 mg/kg, po) or cysteamine HC1 (170 mg/kg, ip) were administered 12 hr after GAL. Hepatic NPSH levels were determined using Ellman's reagent. Hepatic cysteamine levels were determined by separating NPSH Ellman's derivatives by reversed phase HPLC. Cystamine and cysteamine caused transient elevation of NPSH levels of 1-2 nanomoles/mg liver which correlated with the presence of 1-2 nanomoles of cysteamine/mg liver. However, neither cystamine nor cysteamine prevented NPSH levels from falling to 3 nanomoles/mg tissue 24 hr after GAL. Hepatoprotective treatments did not affect long term NPSH status in GAL-poisoned rats. However, transient NPSH increases, due to the intrahepatic presence of cysteamine, may contribute to the therapeutic effects of these hepatoprotective agents.
D000818:Animals; D002851:Chromatography, High Pressure Liquid; D003538:Cystamine / Q000627:therapeutic use*; D003543:Cysteamine / Q000378:metabolism* / Q000627:therapeutic use; D005688:Galactosamine / Q000506:poisoning*; D008099:Liver / Q000378:metabolism*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013438:Sulfhydryl Compounds / Q000378:metabolism*; D013997:Time Factors
D013438:Sulfhydryl Compounds; D003543:Cysteamine; D005688:Galactosamine; D003538:Cystamine